Literature DB >> 15010149

Prophylactic factor replacement in hemophilia.

Manuel D Carcao1, Louis Aledort.   

Abstract

Prophylaxis, the regular infusion of coagulation factor concentrates to severe hemophiliacs, has been an evolving therapeutic tool of management for the past three decades. Multiple clinical trials have and continue to be conducted in the field of prophylaxis in an attempt to determine ideal regimens of prophylaxis, its benefits, its risks and costs, and to address still unanswered questions; who to place on prophylaxis, when to start prophylaxis, when (if ever) to stop prophylaxis, etc. We present a detailed review and discussion of the evolution of prophylaxis as a tool in managing patients with hemophilia and we address the major issues and still unanswered questions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010149     DOI: 10.1016/S0268-960X(03)00038-9

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  8 in total

1.  Need for Prophylactic Treatment in Adult Haemophilia A Patients.

Authors:  Berthold Siegmund; Heinrich Richter; Hartmut Pollmann
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

2.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 3.  Factor VIII replacement is still the standard of care in haemophilia A.

Authors:  Louis Aledort; Pier Mannuccio Mannucci; Wolfgang Schramm; Michael Tarantino
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

4.  Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

Authors:  Jonathan H Foley; Karl-Uwe Petersen; Catherine J Rea; Lori Harpell; Sandra Powell; David Lillicrap; Michael E Nesheim; Benny Sørensen
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

Review 5.  Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.

Authors:  James E Frampton; Antona J Wagstaff
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions.

Authors:  Shannon C Jackson; Ming Yang; Leonard Minuk; Michelle Sholzberg; Jean St-Louis; Alfonso Iorio; Robert Card; Man-Chiu Poon
Journal:  BMC Hematol       Date:  2015-02-14

7.  Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes.

Authors:  Natalie Mathews; Fred G Pluthero; Margaret L Rand; Ann Marie Stain; Manuel Carcao; Victor S Blanchette; Walter H A Kahr
Journal:  Res Pract Thromb Haemost       Date:  2022-09-26

Review 8.  Hemophilia therapy: the future has begun.

Authors:  Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2020-02-14       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.